Research for Treatment of Sensorineural Hearing Loss

You are here

Research for Treatment of Sensorineural Hearing Loss

Wed, 02/26/2014

FDA-Regulated Study of Cord Blood Stem Cells to Treat Acquired Hearing Loss Signals Potential of Newborn Stem Cells in Regenerative Medicine for Common Disorders

SAN BRUNO, CA – [January 16, 2014] – Cord Blood Registry® (CBR®), the world’s largest and most experienced newborn stem cell company, announces the start of a U.S. Food and Drug (FDA)-regulated study being conducted at Florida Hospital for Children in Orlando to investigate the use of a child’s stem cells from their own stored umbilical cord blood as a treatment for acquired sensorineural hearing loss. The FDA trial, supported by CBR, follows promising evidence from preclinical studies suggesting that the infusion of human umbilical cord stem cells may help repair damaged cells in the inner ear in ways that could lead to hearing improvement.

[Read more]